Measurement of true salicylate concentrations in serum from patients with Reye's syndrome.
Patients with Reye's syndrome who have been given aspirin are said to maintain higher-than-anticipated salicylate concentrations in blood, for longer than expected. We explored whether this could be attributed to spurious results from nonsalicylate compounds in the Trinder reaction for salicylates. All of 63 organic acids and amines examined that form colored complexes with Trinder's reagent had detectable absorbance at 540 nm at 0.2 g/L, including some endogenous compounds known to be increased in Reye's syndrome patients and many others endogenous in humans. By subjecting deproteinized sera to thin-layer chromatography and eluting the salicylate fraction before complexing it with ferric ion, true salicylate can be measured quantitatively and differentiated from interfering compounds. In addition, when we examined the effect of salicylate on palmitate binding to serum proteins, we found that salicylate concentrations of 0.2 g/L displaced [16-14C]palmitate binding to protein more in Reye's syndrome patients than in Reye's syndrome survivors or children with influenza. This suggests the presence of atypical binding characteristics for salicylate and palmitate in the acute disorder but not in survivors or children with influenza.
D001241:Aspirin / Q000627:therapeutic use*; D001798:Blood Proteins / Q000378:metabolism; D002648:Child; D002712:Chlorides; D002855:Chromatography, Thin Layer; D005189:False Positive Reactions; D005290:Ferric Compounds; D006801:Humans; D010168:Palmitates / Q000378:metabolism; D011485:Protein Binding; D012202:Reye Syndrome / Q000097:blood* / Q000188:drug therapy; D012459:Salicylates / Q000097:blood* / Q000302:isolation & purification; D013053:Spectrophotometry
D001798:Blood Proteins; D002712:Chlorides; D005290:Ferric Compounds; D010168:Palmitates; D012459:Salicylates; D001241:Aspirin; C024555:ferric chloride